Doximity (NYSE:DOCS) CAO Sells $54,043.54 in Stock

Doximity, Inc. (NYSE:DOCS) CAO Siddharth Sitaram sold 2,077 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $26.02, for a total transaction of $54,043.54. Following the sale, the chief accounting officer owned 96,045 shares in the company, valued at approximately $2,499,090.90. This trade represents a 2.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Siddharth Sitaram also recently made the following trade(s):

• On Thursday, August 13th, Siddharth Sitaram sold 1,770 shares of Doximity stock. The stock was sold at an average price of $24.94, for a total transaction of $44,143.80.

Doximity Stock Down 2.2%

NYSE DOCS opened at $25.99 on Friday. The stock’s 50-day simple moving average is $24.08 and its two-hundred day simple moving average is $23.15. Doximity, Inc. has a twelve month low of $17.15 and a twelve month high of $76.51. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of 30.58, a PEG ratio of 20.78 and a beta of 1.25.

Doximity (NYSE:DOCS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%.Doximity’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 earnings per share. On average, equities analysts expect that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

Institutional Trading of Doximity

Several hedge funds and other institutional investors have recently bought and sold shares of DOCS. Capital World Investors increased its stake in shares of Doximity by 5.1% in the fourth quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock worth $250,398,000 after buying an additional 273,444 shares during the period. Carmignac Gestion boosted its position in Doximity by 127.8% during the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock valued at $100,480,000 after buying an additional 2,418,971 shares during the period. Renaissance Technologies LLC grew its holdings in Doximity by 29.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after acquiring an additional 694,300 shares during the last quarter. Wellington Management Group LLP grew its holdings in Doximity by 24.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after acquiring an additional 621,464 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Doximity by 3,403.2% in the first quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock valued at $32,820,000 after acquiring an additional 1,368,388 shares during the period. Institutional investors own 87.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on DOCS shares. Barclays increased their price target on shares of Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a research report on Friday, August 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Doximity in a research note on Friday, August 7th. Bank of America reaffirmed an “underperform” rating and set a $20.00 target price (down from $38.00) on shares of Doximity in a report on Monday, June 29th. Stifel Nicolaus set a $27.00 target price on shares of Doximity in a research report on Tuesday, September 8th. Finally, Zacks Research raised shares of Doximity from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $32.18.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Analyst sentiment remains mixed but includes meaningful upside: Doximity has an average analyst price target of approximately $32.18, while Piper Sandler maintains an “overweight” rating and recently raised its target to $47.00.
• Neutral Sentiment: Chief Accounting Officer Siddharth Sitaram sold 2,077 shares for approximately $54,044 under a pre-arranged Rule 10b5-1 plan. The filing said the transaction was intended to cover tax withholding related to vested equity awards, reducing its significance as a discretionary bearish signal. Doximity CAO Stock Sale
• Negative Sentiment: Multiple firms announced or promoted a securities class action against Doximity and certain officers, covering investors who purchased shares between August 8, 2024, and May 13, 2026. Investors have until November 16, 2026, to seek appointment as lead plaintiff. The announcements raise litigation, reputational and potential financial-liability concerns, although the allegations have not been adjudicated. Kaplan Fox Doximity Class Action Alert
• Negative Sentiment: A separate investigation is examining whether Doximity’s officers and directors breached fiduciary duties, adding to uncertainty around corporate governance and the company’s legal exposure. Grabar Law Doximity Investigation

About Doximity

Doximity, Inc operates a digital platform for U.S. medical professionals. Its network enables physicians and other healthcare providers to communicate, collaborate, access medical news and research, maintain professional profiles, and connect with colleagues and patients.

The company offers a range of tools for healthcare organizations and professionals, including telehealth services, digital faxing, scheduling and communication products, and solutions for recruiting and marketing. Doximity also provides pharmaceutical and healthcare companies with digital engagement services designed to reach medical professionals through its platform.

Founded in 2010, Doximity is headquartered in San Francisco and primarily serves the United States healthcare market.